Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sichuan Cancer Hospital and Research Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age ≥18 years
2. Diagnosis of advanced NSCLC with clear pathology and brain metastases confirmed by MRI or CT scan of the brain or meningeal metastases confirmed by imaging or lumbar puncture cerebrospinal fluid cytology
3. ALK fusion mutation confirmed by tumor histology or hematology
4. Treatment with lorlatinib from June 2022 to June 2023
5. Survival greater than 12 weeks
You may not be if
Patients treated with lorlatinib for less than 4 weeks
Clareo Health | A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
